Neurol. praxi. 2009;10(3):148-152

Treatment of spasticity in chronic spinal cord injury

doc. MUDr. Ivana Štětkářová CSc
Neurologické oddělení Nemocnice Na Homolce, Praha

Severe spasticity and painfull muscle spasms worsen quality of life, mobility and self-care in patients suffered form chronic spinal cord

injury. Poorly managed spasticity leads to serious long-term complications such as pressure sores, chronic pain, infections and fixed

muscle contractures. Ashworth scale of muscle hypertonia, frequency of muscle spasms and visual analogue scales are the most common

ones used in clinical practice for evaluation of spasticity. The most common treatment of spasticity is oral drug therapy (benzodiazepines,

tizanidine, and baclofen). A local administration of botulinum toxin is suitable for focal spasticity in a small muscle group. In severe flexed

spasticity, ablation procedures may be performed, such as selective peripheral neurotomy, lateral longitudinal myelotomy and posterior

rhizotomy. Physical treatment is also very important. In severe generalized spasticity a long-term treatment often needs higher oral

doses of drugs or various drug combinations, which leads to exaggeration of general adverse effects. Intrathecal continuous baclofen

administration could resolve this problem. Management of spasticity is a long-term process and it needs multidisciplinary approach to

achieve the real treatment goal for each patient.

Keywords: spasticity, spinal cord injury, pharmacotherapy, botulinum toxin, intrathecal baclofen.

Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štětkářová I. Treatment of spasticity in chronic spinal cord injury. Neurol. praxi. 2009;10(3):148-152.
Download citation

References

  1. Ashworth B. Preliminary trial of carisprodol in multiple sclerosis. Practitioner 1964; 192: 540-542.
  2. Bohannon RW, Smith MB. Interrater reliability of modified Ashworth scale of muscle spasticity. Phys Ther 1986; 67: 206-207. Go to original source... Go to PubMed...
  3. Coffey RJ, Edgar TS, Francisco GE, Graziani V, Meythaler J, Ridgely PI. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil; 2002; 83(6): 735-741. Go to original source... Go to PubMed...
  4. Coffey RJ, Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: Report and observation in 41 patients. Neurosurgery 2002; 50: 78-86. Go to original source... Go to PubMed...
  5. Deer TR, Raso LJ, Garten TG. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: A report of two cases and review of the identification and treatment of the complication. Pain Medicine 2007; 8(3): 259-262. Go to original source... Go to PubMed...
  6. Dressnandt J, Auer C, Conrad B. Influence of Baclofen upon the alpha-motoneuron in spasticity by means of F-wave analysis. Muscle Nerve 1995; 18(1): 103-107. Go to original source... Go to PubMed...
  7. Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997; 35(10): 686-689. Go to original source... Go to PubMed...
  8. Kaňovský P. Patofyziologie spasticity v dospělosti. In: Kaňovský P, Bareš M, Dufek J a kol. (Eds). Spasticita, mechanismy diagnostika, léčba. Jessenius Maxdorf. 2004: 83-88.
  9. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: disordered motor control. Chicago: Yearbook Medical. 1980: 485-494.
  10. Lazorteh Y, Sol JC, Sallerin B, Verdié JC. The surgical management of spasticity. European J Neurology 2002; 9: 35-41. Go to original source... Go to PubMed...
  11. Kamen L, Henney HR, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke and spinal cord injury. Curr Med Res Opin 2008; 24(2): 425-439. Go to original source... Go to PubMed...
  12. Marciniak C, Rader L, Gagnon C. The use of botulinum toxin for spasticity after spinal cord injury. Am J Phys Med Rehab 2008; 87(4): 312-317. Go to original source... Go to PubMed...
  13. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle and Nerve 1997; (Suppl. 6): S1-13. Go to original source...
  14. Meythaler JM, Roper JF, Brunner RC. Cyproheptadine for intrathecal baclofen withdrawal. Arch Phys Med Rehabil 2003; 84: 638-642. Go to original source... Go to PubMed...
  15. Medical Research Council of the UK. Aids to the Investigation of Peripheral Nerve Injuries. Memorandum No. 45. London: Pendragon House. 1976: 6-7.
  16. Noreau L, Proulx P, Gagnon L, Drolet M, Laramee MT. Secondary impairments after spinal cord injury: a populationbased study. Am J Phys Med Rehabil 2000; 79: 526-535. Go to original source... Go to PubMed...
  17. Ochs G, Naumann C, Dimitrijevic M, Sindou M. Intrathecal baclofen therapy for spinal origin spasticity. spinal cord injury, spinal cord disease, and multiple sclerosis. Neuromodulation 1999; 2(2): 108-119. Go to original source... Go to PubMed...
  18. Ordia JI, Fischer E, Adamski E, Spatz EL. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996; 85: 452-457. Go to original source... Go to PubMed...
  19. Pandyan AD, Gregoric M, Barnes MP, Wood D, Van Wijck F, Burridge J, Hermens H, Johnson GR. Spasticity: clinical perceptions, neurological realities amd meaningful measurement. Disabil Rehabil 2005; 27: 2-6. Go to original source... Go to PubMed...
  20. Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1984; 1: 1078. Go to original source... Go to PubMed...
  21. Pierrot-Deseilligny E. Electrophysiological assessment of the spinal mechanisms underlying spasticity. In: Rossini PM, Mauguiere F, eds. New Trends and Advanced Techniques in Clinical Neurophysiology (EEG Suppl. 41). Elsevier Science Publishers: B.V., 1990: 264-273. Go to original source... Go to PubMed...
  22. Sheen G. The pathophysiology of spasticity. European J Neurology 2002; 9: 3-9. Go to original source... Go to PubMed...
  23. Snow BJ, Tsuji JKC, Bhart MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 1990; 28: 512-515. Go to original source... Go to PubMed...
  24. Stokic DS, Yablon SA, Hayes A. Comparison of clinical and neurophysiologic responses to Intrathecal baclofen bolus administration in moderate-to-severe spasticity after acquired brain injury. Arch Physiol Med Rehab 2005; 86(9): 1801-1806. Go to original source... Go to PubMed...
  25. Tichý M, Kraus J, Hořínek D, Vaculík M. Selective posterior rhizotomy in the treatment of cerebral palsy, first experience in Czech Republic. Bratisl Lék Listy 2003; 104(2): 54-58. Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.